Related references
Note: Only part of the references are listed.Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Ryoichi Saito et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Yu Fu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Bonnie S. Glisson et al.
CLINICAL CANCER RESEARCH (2020)
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
Veronica Mollica et al.
CLINICAL DRUG INVESTIGATION (2019)
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang et al.
CLINICAL CANCER RESEARCH (2019)
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Yayi He et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist
Fanny Polesso et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy
Anja Kathrin Wege
BIODRUGS (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors
Rui Wang et al.
CANCER RESEARCH (2018)
Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
Richard Bryan Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies
A. Diab et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Cancer immunotherapy: Historical Perspective of a Clinical Revolution and emerging Preclinical Animal Models
William K. Decker et al.
FRONTIERS IN IMMUNOLOGY (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).
Scott Joseph Antonia et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer
Benjamin Weixler et al.
ONCOTARGET (2015)
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
Zhiqiang Guo et al.
PLOS ONE (2014)
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
David A. Schaer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Science gone translational: the OX40 agonist story
Andrew D. Weinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Silvia Piconese et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Share Paper
